ArticleScientific reports2024

Plasma proteome profiling reveals the therapeutic effects of the PPAR pan-agonist chiglitazar on insulin sensitivity, lipid metabolism, and inflammation in type 2 diabetes.

Xingyue Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.